Novo Holdings silent on newly created company with million-dollar backing
USD 2.8m (DKK 18m) has been granted to the subsidiary Orbis Medicines, which Novo Holdings founded this week. The holding company doesn't want to comment on anything regarding the new company, however, just as the new director remains silent.
BY CHRISTOPHER DUE KARLSSON, TRANSLATED BY DANIEL PEDERSEN
This week, Novo Nordisk fund Novo Holdings founded a new subsidiary named Orbis Medicines, which was at the same time afforded DKK 18m (USD 2.8m), according to registrations in the Danish Central Business Register (CVR). For the time being, however, Novo Nordisk won't comment on the establishment of Orbis Medicines, it tells MedWatch in an email.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Novo Holdings considers sale of Xellia Pharmaceuticals
For subscribers
.jpg&w=384&q=75)
